Last reviewed · How we verify

Perioperative Tachycardia — Treatment Landscape & Competitive Intelligence

Perioperative Tachycardia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Perioperative Tachycardia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Brevibloc In Plastic Container ESMOLOL Pfizer beta-Adrenergic Blocker Beta-1 adrenergic receptor 1986-01-01
Brevibloc Brevibloc AOP Orphan Pharmaceuticals AG Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AOP Orphan Pharmaceuticals AG · 1 drug in Perioperative Tachycardia
  2. Pfizer · 1 drug in Perioperative Tachycardia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Perioperative Tachycardia:

Cite this brief

Drug Landscape (2026). Perioperative Tachycardia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/perioperative-tachycardia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing